File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Using bevacizumab in the fight against malignant glioma: First results in Asian patients

TitleUsing bevacizumab in the fight against malignant glioma: First results in Asian patients
Authors
KeywordsAntineoplastic combined chemotherapy protocols
Brain neoplasms
Glioblastoma
Local
Neoplasm recurrence
Treatment outcome
Issue Date2011
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
Citation
Hong Kong Medical Journal, 2011, v. 17 n. 4, p. 274-279 How to Cite?
AbstractObjectives To investigate the efficacy and safety profile of bevacizumab in combination with irinotecan in Hong Kong Chinese patients with recurrent malignant glioma and to determine whether their response differed from that reported in other populations. Design Retrospective study. Setting Two private clinics and a public hospital in Hong Kong. Patients Fourteen individuals who presented with recurrent glioma presenting to the hospital between November 2005 and November 2009. Intervention Salvage therapy with bevacizumab (10 mg/kg) and irinotecan (125 mg/m 2 [340 mg/m 2 for those taking enzyme-inducing antiepileptic drugs]) on a 14-day schedule. Results A radiological response was observed in 12 (86%) of the patients, four (33%) of whom had a complete response. The median progression-free survival was 6 (range, 1-15) months; 71% remained progression-free at 6 months. The median overall survival was 18 (range, 9-61) months. The most common adverse events during the bevacizumab and irinotecan treatment period were haematological; five patients had grade 2/3 adverse events. Pulmonary embolism occurred in two patients, one of whom died. Intracranial haemorrhage was not detected in any of the 14 treated patients. Conclusions Bevacizumab plus irinotecan was at least as effective at treating Chinese patients with recurrent glioma as previously reported in clinical trials in different patient populations.
Persistent Identifierhttp://hdl.handle.net/10722/137560
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279
References

 

DC FieldValueLanguage
dc.contributor.authorPu, JKSen_HK
dc.contributor.authorChan, RTTen_HK
dc.contributor.authorNg, GKBen_HK
dc.contributor.authorLeung, GKKen_HK
dc.contributor.authorHung, KNen_HK
dc.contributor.authorFung, CFen_HK
dc.date.accessioned2011-08-26T14:27:57Z-
dc.date.available2011-08-26T14:27:57Z-
dc.date.issued2011en_HK
dc.identifier.citationHong Kong Medical Journal, 2011, v. 17 n. 4, p. 274-279en_HK
dc.identifier.issn1024-2708en_HK
dc.identifier.urihttp://hdl.handle.net/10722/137560-
dc.description.abstractObjectives To investigate the efficacy and safety profile of bevacizumab in combination with irinotecan in Hong Kong Chinese patients with recurrent malignant glioma and to determine whether their response differed from that reported in other populations. Design Retrospective study. Setting Two private clinics and a public hospital in Hong Kong. Patients Fourteen individuals who presented with recurrent glioma presenting to the hospital between November 2005 and November 2009. Intervention Salvage therapy with bevacizumab (10 mg/kg) and irinotecan (125 mg/m 2 [340 mg/m 2 for those taking enzyme-inducing antiepileptic drugs]) on a 14-day schedule. Results A radiological response was observed in 12 (86%) of the patients, four (33%) of whom had a complete response. The median progression-free survival was 6 (range, 1-15) months; 71% remained progression-free at 6 months. The median overall survival was 18 (range, 9-61) months. The most common adverse events during the bevacizumab and irinotecan treatment period were haematological; five patients had grade 2/3 adverse events. Pulmonary embolism occurred in two patients, one of whom died. Intracranial haemorrhage was not detected in any of the 14 treated patients. Conclusions Bevacizumab plus irinotecan was at least as effective at treating Chinese patients with recurrent glioma as previously reported in clinical trials in different patient populations.en_HK
dc.languageengen_US
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.htmlen_HK
dc.relation.ispartofHong Kong Medical Journalen_HK
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectAntineoplastic combined chemotherapy protocolsen_HK
dc.subjectBrain neoplasmsen_HK
dc.subjectGlioblastomaen_HK
dc.subjectLocalen_HK
dc.subjectNeoplasm recurrenceen_HK
dc.subjectTreatment outcomeen_HK
dc.subject.meshAngiogenesis Inhibitors - therapeutic use-
dc.subject.meshAntibodies, Monoclonal, Humanized - therapeutic use-
dc.subject.meshBrain Neoplasms - drug therapy - mortality-
dc.subject.meshGlioblastoma - drug therapy-
dc.subject.meshGlioma - drug therapy - mortality-
dc.titleUsing bevacizumab in the fight against malignant glioma: First results in Asian patientsen_HK
dc.typeArticleen_HK
dc.identifier.emailLeung, GKK: gilberto@hkucc.hku.hken_HK
dc.identifier.authorityLeung, GKK=rp00522en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.pmid21813894-
dc.identifier.scopuseid_2-s2.0-80052954219en_HK
dc.identifier.hkuros191517en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80052954219&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume17en_HK
dc.identifier.issue4en_HK
dc.identifier.spage274en_HK
dc.identifier.epage279en_HK
dc.publisher.placeHong Kongen_HK
dc.identifier.scopusauthoridPu, JKS=35094475800en_HK
dc.identifier.scopusauthoridChan, RTT=52663172800en_HK
dc.identifier.scopusauthoridNg, GKB=37065177500en_HK
dc.identifier.scopusauthoridLeung, GKK=35965118200en_HK
dc.identifier.scopusauthoridHung, KN=7202728375en_HK
dc.identifier.scopusauthoridFung, CF=52663351500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats